Kera Capital Partners Inc. Makes New $218,000 Investment in Edwards Lifesciences Co. (NYSE:EW)

Kera Capital Partners Inc. acquired a new stake in Edwards Lifesciences Co. (NYSE:EW) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,942 shares of the medical research company’s stock, valued at approximately $218,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. FSA Wealth Management LLC acquired a new position in Edwards Lifesciences in the third quarter valued at approximately $30,000. Prospera Private Wealth LLC acquired a new position in shares of Edwards Lifesciences in the 3rd quarter valued at $32,000. Avior Wealth Management LLC boosted its holdings in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after buying an additional 308 shares in the last quarter. Peoples Bank KS acquired a new stake in Edwards Lifesciences during the third quarter valued at $40,000. Finally, JFS Wealth Advisors LLC increased its holdings in Edwards Lifesciences by 31.1% in the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after buying an additional 166 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $69.77 on Monday. The firm has a 50 day simple moving average of $72.06 and a 200-day simple moving average of $71.32. The stock has a market cap of $41.15 billion, a price-to-earnings ratio of 10.07, a price-to-earnings-growth ratio of 3.77 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter last year, the firm earned $0.59 earnings per share. The firm’s quarterly revenue was up 8.9% compared to the same quarter last year. On average, analysts expect that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 2,500 shares of the firm’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 33,000 shares of company stock valued at $2,195,180 over the last 90 days. 1.27% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on EW shares. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. Barclays raised their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a report on Monday, December 2nd. The Goldman Sachs Group increased their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. Piper Sandler cut their price target on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $78.48.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.